Fig. 4: Treatments interfering with HAS3 and CD44 combined with autophagy inhibitors exert synergistic effects on glioma cell viability and autophagy levels. | Cell Death & Disease

Fig. 4: Treatments interfering with HAS3 and CD44 combined with autophagy inhibitors exert synergistic effects on glioma cell viability and autophagy levels.

From: Interfering with hyaluronic acid metabolism suppresses glioma cell proliferation by regulating autophagy

Fig. 4: Treatments interfering with HAS3 and CD44 combined with autophagy inhibitors exert synergistic effects on glioma cell viability and autophagy levels.The alternative text for this image may have been generated using AI.

A Relative levels of the P62 and MAP1LC3B proteins in U251 glioma cells transfected with the HAS3 siRNA or cultured with a CD44 antibody, followed by treatment with CQ (30 μmol/L) for 48 h. B Viability of U251 glioma cells transfected with the HAS3 siRNA or cultured with a CD44 antibody, followed by treatment with CQ (30 μmol/L) for 48 h. C–D Levels of the Ki67 protein in U251 glioma cells were detected using immunofluorescence staining after transfection with the HAS3 siRNA or culture with a CD44 antibody, followed by treatment with CQ (30 μmol/L) for 48 h. Scale bar: 50 μm. The data are presented as the mean ± SD; *P < 0.05, **P < 0.01, and ***P < 0.001, ****P < 0.0001.

Back to article page